A Single dose, two-way crossover study of the bioequivalence of two formulations of Ribavirin

A Single dose, two-way crossover study of the bioequivalence of two formulations of Ribavirin - BE of Ribavirin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36756

Enrollment

Registered

2011-04-11

Start date

2011-05-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

Active substance: ribavirin

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 18-55 years, BMI 18-30 kg/m2 (inclusive) man or postmenopausal women

Exclusion criteria

Exclusion criteria: Suffering from: hepatitis B, cancer or HIV/Aids. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months preceding the start of this study.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics Safety	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)